N-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethyl]-2-oxo-1,3-dihydrobenzimidazole-5-sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethyl]-2-oxo-1,3-dihydrobenzimidazole-5-sulfonamide
• 化学式: C₂₁H₂₅FN₄O₃S
• 分子量: 432.5
• InChiKey: FVWMEAWUUSSELW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  98.9
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS
  申请人：Psychogenics Inc.

  公开号：EP2858649A2

  公开（公告）日：2015-04-15
• [EN] TREATMENT OF MOTOR AND MOVEMENT DISORDER SIDE EFFECTS ASSOCIATED WITH PARKINSON'S DISEASE TREATMENTS<br/>[FR] TRAITEMENT DES EFFETS SECONDAIRES DES TROUBLES MOTEURS ET DE LA DYSKINÉSIE ASSOCIÉS AUX TRAITEMENTS ANTIPARKINSONIENS
  申请人：PSYCHOGENICS INC

  公开号：WO2013188210A2

  公开（公告）日：2013-12-19

  This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.